Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962221 | 0.91 | TLR7 (0.40) | TLR7DYRK1A | |
| SCHEMBL1961220 | 0.87 | MRGPRX4 (0.39) | TLR7TLR8 | |
| SCHEMBL1959277 | 0.84 | TLR7 (0.47) | TLR7KMT2AMEN1TLR8NUDT1 | |
| SCHEMBL1486567 | 0.79 | TLR7 (0.62) | TLR7TLR8NUDT1 | |
| SCHEMBL1486528 | 0.77 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL1486575 | 0.75 | NMT1 (0.45) | TLR7HRH3ACSS2 | |
| SCHEMBL1486507 | 0.73 | TLR7 (0.47) | TLR7KMT2AMEN1HRH3TLR8 | |
| SCHEMBL1486524 | 0.72 | TLR7 (0.40) | TLR7MAOBKMT2ARAB9AMEN1 | |
| SCHEMBL1486506 | 0.72 | TLR7 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL12315583 | 0.72 | TLR7 (0.56) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658076-B1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8263594-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | TLR7 42/4885MAOB 3039/4885KMT2A 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.